PubRank

L Balant

Author PubWeight™ 40.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinet 1985 1.70
2 Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats. Clin Ther 1980 1.44
3 Renal failure, drug pharmacokinetics and drug action. Clin Pharmacokinet 1976 1.29
4 [Pharmacokinetics of a new cephalosporin, cefoperazone]. Schweiz Med Wochenschr 1979 1.20
5 Kinetics of blood component adsorption on poly(D,L-lactic acid) nanoparticles: evidence of complement C3 component involvement. J Biomed Mater Res 1997 1.09
6 Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. Pharm Acta Helv 1998 1.06
7 The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet 1982 0.99
8 Adrenergic modification of glucose-induced biphasic insulin release from perifused rat pancreas. Eur J Clin Invest 1971 0.96
9 Dynamic aspects of proinsulin release from perifused rat pancreas. Lancet 1969 0.92
10 Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol 1982 0.91
11 Perifusion of rat pancreatic tissue in vitro: substrate modification of theophylline-induced biphasic insulin release. J Clin Invest 1970 0.91
12 Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol 1975 0.91
13 Salivary electrolytes and digitalis. Eur Heart J 1983 0.91
14 [Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality]. Schweiz Med Wochenschr 1976 0.89
15 Urinary protein analysis with sodium dodecylsulfate polyacrylamide gel electrophoresis: a comparison with other analytical techniques. Clin Chim Acta 1974 0.88
16 Simultaneous tubular excretion and reabsorption of pindolol in man. Eur J Clin Pharmacol 1981 0.87
17 Behaviour of glibenclamide on repeated administration to diabetic patients. Eur J Clin Pharmacol 1977 0.86
18 Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents. Clin Pharmacokinet 1980 0.85
19 Recent drug management advances in renal insufficiency. Adv Nephrol Necker Hosp 1974 0.85
20 Metabolic state, pancreatic insulin content and B-cell morphology of normoglycemie spiny mice (Acomys cahirinus): indications for an impairment of insulin secretion. Diabetologia 1970 0.85
21 [Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol]. Schweiz Med Wochenschr 1978 0.84
22 Influence of renal failure on the hepatic clearance of bufuralol in man. J Pharmacokinet Biopharm 1980 0.84
23 [Regulation of insulin release in perifused pancreatic tissue]. Acta Diabetol Lat 1969 0.83
24 Clinical relevance of different electrophoretic methods for the analysis of urinary proteins. Curr Probl Clin Biochem 1979 0.82
25 Polymorphism in drug metabolism. Br Med J 1978 0.81
26 Determination of human alcohol dehydrogenase and acetaldehyde dehydrogenase genotypes by single strand conformation polymorphism in discontinuous buffer electrophoresis. Electrophoresis 1993 0.81
27 The genetic control of drug oxidation in the liver. Int J Clin Pharmacol Res 1983 0.81
28 [Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation]. Schweiz Med Wochenschr 1983 0.80
29 [D-xylose absorption test. A pharmacokinetic and statistical study]. Schweiz Med Wochenschr 1978 0.80
30 [Pharmacokinetics of bufuralol in man]. Pharm Acta Helv 1978 0.80
31 Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin Pharmacol 1985 0.80
32 Influence of genetic variation in alcohol and aldehyde dehydrogenase on serotonin metabolism. Life Sci 1994 0.79
33 Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet 1981 0.79
34 Des 4-trans-hydroxy-glibenclamide show hypoglycemic activity? Arzneimittelforschung 1979 0.79
35 Analysis of proteinuria in health and disease using sodium dodecyl sulphate-acrylamide gel electrophoresis. Eur J Clin Invest 1974 0.78
36 Density of guanine nucleotide-binding proteins in platelets of patients with major depression: increased abundance of the G alpha i2 subunit and down-regulation by antidepressant drug treatment. Biol Psychiatry 1997 0.77
37 Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenkr (1970) 1982 0.77
38 Enantioselective analysis of methadone in saliva by liquid chromatography-mass spectrometry. J Chromatogr A 2000 0.77
39 Micro gel electrophoresis modification for dilute (protein) solutions. Anal Biochem 1970 0.77
40 Decreased extrarenal clearance of cefoperazone in hepatocellular diseases. Br J Clin Pharmacol 1981 0.77
41 The metabolic response of lean and obese mice to prolonged fasting. Horm Metab Res 1974 0.77
42 Rapid detection of the main human plasma glycoproteins by two-dimensional polyacrylamide gel electrophoresis lectin affinoblotting. Electrophoresis 1995 0.77
43 Internalization of poly(D,L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorbed onto the particles. J Biomed Mater Res 1994 0.76
44 High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer. Eur J Clin Pharmacol 1987 0.76
45 Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973 0.76
46 [Pharmacokinetic study of a cephalosporin, cefoperazone, in liver failure]. Schweiz Med Wochenschr 1981 0.75
47 Prediction from plasma pools in pharmacokinetic studies: a comment. Fundam Clin Pharmacol 1993 0.75
48 Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. Eur Arch Psychiatry Neurol Sci 1984 0.75
49 [Influence of deficient kidney function on behavior of glipizide (hypoglycemic sulfonylurea) and its metabolites]. J Urol Nephrol (Paris) 1973 0.75
50 Basis for dosing time-dependent changes in the ocular and systemic absorption of topically applied timolol. J Ocul Pharmacol Ther 1996 0.75
51 [Depressive states in the elderly and their treatment]. Schweiz Med Wochenschr 1986 0.75
52 Intraperitoneal test of insulin activity on the rat diaphragm in vivo: factors controlling the variability of response. Acta Endocrinol (Copenh) 1972 0.75
53 [Electrocardiograms of digitalis intoxication. Reevaluation]. Schweiz Med Wochenschr 1976 0.75
54 Insulin of spiny mice (Acomys cahirinus)--partial characterization and evidence for two insulins. Endocrinology 1971 0.75
55 [Proceedings: Alkaline phosphatases in patients in chronic hemodialysis]. Schweiz Med Wochenschr 1975 0.75
56 Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet 1987 0.75
57 [Physiological proteinuria. Data of acrylamide-SDS gel electrophoresis and other methods of qualitative and quantitative analysis]. Schweiz Med Wochenschr 1975 0.75
58 [Influence of chronic renal failure on the D-xylose test in man]. Gastroenterol Clin Biol 1988 0.75
59 Catabolism physical, and immunologic properties of endocytosed isologous and heterologous iota-globulins by mouse macrophages. J Immunol 1975 0.75
60 [Problems encountered in the pharmacological treatment of depression (resistance to treatment, metabolic problems, undesirable secondary effects, non-compliance)]. Rev Med Suisse Romande 1987 0.75
61 [Clinical pharmacokinetics]. Schweiz Med Wochenschr 1976 0.75
62 [Therapy compliance. A matter of concern in clinical medicine]. Schweiz Rundsch Med Prax 1992 0.75
63 Insulin and insulin inhibitor on amino acid transport in rat diaphragm in vivo. Biochim Biophys Acta 1975 0.75
64 [Treatment of schizophrenia with powerful neuroleptics]. Rev Med Suisse Romande 1986 0.75
65 [Inter- and intra-individual variations on the disposition of piroxicam. Pharmacokinetics in healthy man and the patient with renal insufficiency]. Pharm Acta Helv 1982 0.75
66 [Quantitative approach to drug compliance of diabetics]. Schweiz Med Wochenschr 1983 0.75
67 [Clearance concept applied to pharmacokinetics: 1. Application for the study of tolamolol (beta-blocking agent) in healthy volunteers (author's transl)]. Nephrologie 1980 0.75
68 [The effect of lactitol on the production of expired hydrogen in normal subjects]. Schweiz Med Wochenschr 1986 0.75
69 [Alkaline phosphatase isoenzymes. Selection of the seperation methods and their diagnostic value]. Schweiz Med Wochenschr 1975 0.75
70 Comparison of some pharmacokinetic parameters of (+)-cyanidanol-3 obtained with specific and non-specific analytical methods. Arzneimittelforschung 1979 0.75
71 [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)]. Nephrologie 1980 0.75
72 [The usefulness of compartmental analysis for the development of sustained release drug forms; experiences with drotaverine in humans]. Pharm Acta Helv 1979 0.75
73 [Proteinuria]. Rev Med Suisse Romande 1978 0.75
74 [Hepatic clearance of drugs in kidney failure]. Nephrologie 1983 0.75
75 [Effect of age on blood digoxin and digitalization]. Schweiz Med Wochenschr 1974 0.75
76 [The hand in diabetes. Study of 97 diabetics compared to a control group]. Schweiz Med Wochenschr 1979 0.75
77 [Retention of metabolites of a beta-blocking drug, oxprenolol, in renal insufficiency]. Schweiz Med Wochenschr 1981 0.75
78 [Gastrointestinal absorption and multicompartemental analysis using computers]. Pharm Acta Helv 1977 0.75
79 Alcohol flushing, patch test, and ADH and ALDH genotypes in Brazilian ethnic groups. Braz J Med Biol Res 1995 0.75
80 [Application of multicompartimental analysis to the pharmacokinetics of vincamine in man]. Pharm Acta Helv 1977 0.75
81 [Cholestyramine and digoxin intoxication: therapeutic efficacy?]. Schweiz Med Wochenschr 1979 0.75
82 [Metabolites of hypoglycemic sulfonylureas in kidney failure. Experience with glibenclamide]. Schweiz Med Wochenschr 1978 0.75
83 Development of validated stereoselective methods for methadone determination in clinical samples. Chirality 1999 0.75
84 [Hypoglycemic sulfonylurea metabolites: clinical interest. Experiences with glibenclamide in the rat]. Schweiz Med Wochenschr 1977 0.75
85 [Initial aspects of the changes in diabetic proteinuria]. Schweiz Med Wochenschr 1980 0.75
86 [Kinetics of cefoperazone and cefoperazone and cephalothin in rat tissues]. Schweiz Med Wochenschr 1980 0.75
87 [Diagnosis of lactase deficiency with the expired hydrogen (H2) test]. Schweiz Med Wochenschr 1981 0.75
88 Red blood cell protein map: a comparison between carrier-ampholyte pH gradient and immobilized pH gradient, and identification of four red blood cell enzymes. Appl Theor Electrophor 1992 0.75
89 [Blood digoxin level and digitalization]. Schweiz Med Wochenschr 1974 0.75
90 [Kidney and drugs - urinary lithiasis. Pharmacokinetic glossary]. Rev Med Suisse Romande 1980 0.75
91 [Side effects of nalidixic acid in a patient with severe renal failure. Clinical study and proposal of a pharmacokinetic model]. Schweiz Med Wochenschr 1977 0.75
92 [Effect of guar on the gastrointestinal absorption of D-xylose: compartmental analysis on a computer]. Pharm Acta Helv 1978 0.75
93 [Salivary electrolytes, digitalis glycosides and cardiac insufficiency]. Schweiz Med Wochenschr 1978 0.75
94 Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents. Eur J Clin Pharmacol 1983 0.75
95 [Breath hydrogen for detecting lactase deficiency. II. Relation between intestinal lactase activity, breath hydrogen and blood glucose during lactose tolerance test in 73 adult patients (author's transl)]. Gastroenterol Clin Biol 1981 0.75
96 [The exhaled hydrogen test: its value in the quantitative diagnosis of carbohydrate malabsorption]. Schweiz Med Wochenschr 1978 0.75
97 Evaluation of occupational exposure to metallic mercury and of its early renal effects. Dev Toxicol Environ Sci 1980 0.75
98 [A clinical study of a new sulfonylures hypoglycemic agent: glipizide (glibenese)(author's transl)]. Schweiz Rundsch Med Prax 1975 0.75
99 [Diffusion and metabolism of drugs in renal insufficiency]. Rev Prat 1980 0.75
100 Applicability of different types of models in health and disease. Drug Metab Rev 1984 0.75
101 [Pharmacokinetic study of a cephalosporin: cefoperazone in patients with a Kehr drain]. Schweiz Med Wochenschr 1982 0.75
102 [Pharmacokinetics of bacampicillin in man (author's transl)]. Schweiz Rundsch Med Prax 1979 0.75
103 [Proteinuria, hematuria, and glomerular filtrate in glomerulonephritis]. Schweiz Med Wochenschr 1974 0.75
104 [Action of tienilic acid, a diuretic modifying the tubular system of the excretion of organic acids (author's transl)]. Schweiz Rundsch Med Prax 1978 0.75
105 [Bioavailability: concept and problems (author's transl)]. J Pharm Belg 1981 0.75
106 [Pharmacokinetic perturbations in kidney failure. Anomalies of metabolites and tissue diffusion (author's transl)]. Nouv Presse Med 1979 0.75
107 ["First" and "second" generation sulfonylureas: distinction or difference? (author's transl)]. Diabete Metab 1978 0.75
108 [Proteinuria in mature diabetic patients. Quantitative and qualitative analysis]. Schweiz Med Wochenschr 1975 0.75
109 [Breath hydrogen for detecting lactase deficiency. I. Methodological and statistical analysis (author's transl)]. Gastroenterol Clin Biol 1981 0.75
110 [Value and limits of urinary protein electrophoresis with sodium dodecyl sulfate in the evaluation of glomerular nephropathies]. Schweiz Med Wochenschr 1979 0.75
111 [The magician's hat. Problems concerning the analysis of data and the presentation of results in pharmacologic literature]. Schweiz Rundsch Med Prax 1978 0.75